Advice
After ongoing discussions between NICE and CSL Behring UK, NICE is unable to make a recommendation about the use of human alpa1‑proteinase inhibitor for treating emphysema in the NHS.
CSL Behring UK has confirmed that it does not intend to launch the product in England and Wales. The reasons for this decision are primarily related to the company's inability to offer the product at a price to meet the current threshold of cost effectiveness.
The context for this decision is important, and related to the unique, complex and high-cost nature of plasma-derived therapy production.
Information
If NHS organisations wish to consider human alpa1‑proteinase inhibitor for this indication, they should follow the advice on rational local decision making in the NHS Constitution for England and the NHS Commissioning Board and Clinical Commissioning Groups (Responsibilities and Standing Rules) Regulations 2012. This outlines the approach that should be taken when there is no NICE guidance.
If the company wishes to make a submission to NICE in the future for this topic it will be rescheduled back into the work programme.
ISBN: 978-1-4731-5883-2